Lantern Pharma Inc. Investing Cash Flow
Lantern Pharma Inc. (LTRN) reported Investing Cash Flow of $4.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-14
- Lantern Pharma Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $692.25K, a 80.73% decline year-over-year.
- Lantern Pharma Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $4.25M, a 31.20% increase year-over-year.
- Lantern Pharma Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$1.70M, a 149.43% decline year-over-year.
- Lantern Pharma Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $5.93M, a 771.40% increase year-over-year.
- Lantern Pharma Inc. net cash provided by (used in) investing activities for fiscal 2025 was $11.06M, a 228.16% increase from fiscal 2024.
- Lantern Pharma Inc. net cash provided by (used in) investing activities for fiscal 2024 was $3.37M.
- Lantern Pharma Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$930.21K, a 618.89% decline from fiscal 2022.
- Lantern Pharma Inc. net cash provided by (used in) investing activities for fiscal 2022 was $179.27K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $692.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.94M 10-Q · filed 2026-08-14 | $3.24M derived: sum of 3 quarters · filed 2026-08-14 | $9.17M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.25M 10-Q · filed 2026-05-15 | $2.55M derived: sum of 2 quarters · filed 2026-05-15 | $8.47M derived: sum of 3 quarters · filed 2026-05-15 | $12.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.22M derived: sum of 2 quarters · filed 2026-03-30 | $7.82M derived: sum of 3 quarters · filed 2026-08-14 | $11.06M 10-K · filed 2026-03-30 |
| 2025-09-30 | $5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $9.52M derived: sum of 2 quarters · filed 2026-08-14 | $12.76M 10-Q · filed 2025-11-12 | $16.21M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $6.83M 10-Q · filed 2026-08-14 | $10.28M derived: sum of 3 quarters · filed 2026-08-14 | $10.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $3.24M 10-Q · filed 2026-05-15 | $6.69M derived: sum of 2 quarters · filed 2026-05-15 | $7.37M derived: sum of 3 quarters · filed 2026-05-15 | $7.16M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.13M derived: sum of 2 quarters · filed 2026-03-30 | $3.93M derived: sum of 3 quarters · filed 2026-03-30 | $3.37M 10-K · filed 2026-03-30 |
| 2024-09-30 | $680.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $478.28K derived: sum of 2 quarters · filed 2025-11-12 | -$77.89K 10-Q · filed 2025-11-12 | $178.29K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$202.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$758.23K 10-Q · filed 2025-08-13 | -$502.05K derived: sum of 3 quarters · filed 2025-08-13 | -$270.32K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$556.17K 10-Q · filed 2025-05-15 | -$299.99K derived: sum of 2 quarters · filed 2025-05-15 | -$68.26K derived: sum of 3 quarters · filed 2025-05-15 | -$525.50K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $256.18K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $487.91K derived: sum of 2 quarters · filed 2025-03-27 | $30.67K derived: sum of 3 quarters · filed 2025-03-27 | -$930.21K 10-K · filed 2025-03-27 |
| 2023-09-30 | $231.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$225.51K derived: sum of 2 quarters · filed 2024-11-07 | -$1.19M 10-Q · filed 2024-11-07 | -$583.53K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$457.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.42M 10-Q · filed 2024-08-08 | -$815.26K derived: sum of 3 quarters · filed 2024-08-08 | -$889.62K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$960.88K 10-Q · filed 2024-05-09 | -$358.02K derived: sum of 2 quarters · filed 2024-05-09 | -$432.38K derived: sum of 3 quarters · filed 2024-05-09 | -$958.13K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $602.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $528.50K derived: sum of 2 quarters · filed 2024-03-18 | $2.75K derived: sum of 3 quarters · filed 2024-03-18 | $179.27K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$74.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$600.11K derived: sum of 2 quarters · filed 2023-11-08 | -$423.59K 10-Q · filed 2023-11-08 | -$657.55K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$525.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$349.23K 10-Q · filed 2023-08-09 | -$583.19K derived: sum of 3 quarters · filed 2023-08-09 | -$1.59M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $176.52K 10-Q · filed 2023-05-09 | -$57.44K derived: sum of 2 quarters · filed 2023-05-09 | -$1.06M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$233.96K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$1.24M derived: sum of 2 quarters · filed 2023-03-20 | -$19.53M 10-K · filed 2023-03-20 | |
| 2021-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$19.30M 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | -$18.29M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | -$4.99K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$8.32K derived: sum of 2 quarters · filed 2022-03-10 | -$16.14K 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$3.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$11.14K 10-Q · filed 2021-11-01 | ||
| 2020-06-30 | -$7.82K 10-Q · filed 2021-07-29 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$5.72K 10-K · filed 2021-03-10 | ||
| 2019-09-30 | -$5.72K 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |